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Levofloxacin is the L-isomer of the racemate ofloxacin, a quinolone antimicrobial agent. Chemically levofloxacin,  
a chiral fluorinated carboxyquinolone, is the pure (S)-enantiomer of the racemic drug substance Ofloxacin.
1.1  Chemical  Name:  9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-
benzoxazine-6-carboxylic acid, hemihydrate.
1.2 Chemical Formula: C18H20F  N  3O4- H2O
 1
1.3 Chemical Structure: 
1.4 Molecular weight: 361.3675 2
1.5 Melting point:  225-227°C
1.6 Availability: 99% 
1.7 Protein binding: 24 to 38%
1.8 Half-life: 6 to 8 hours
1.9 Appearance: Pale yellow solid crystalline powder.
Abstract
Levofloxacin  is  the  L-isomer  of  the  racemate  ofloxacin,  a  quinolone 
antimicrobial  agent.  Chemically  levofloxacin,  a  chiral  fluorinated 
carboxyquinolone, is the pure (S)-enantiomer of the racemic drug substance 
Ofloxacin.Preformulation studies are needed to ensure the development of a 
stable  as  well  as  therapeutically  effective  and  safe  dosage  form.  The 
Preformulation studies, performed in this research include identification of 
drug, solubility analysis, partition coefficient and drug compatibility.
In  present  work  complete  preformulation  study  was  carried  out, 
which  include  identification  of  drug,  quantitative  estimation  of  drug, 
solubility  determination,  melting  point  determination,partition  coefficient 
determination etc.
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1.10 Solubility: Freely soluble in glacial acetic acid, chloroform; sparingly soluble in water.
1.11  Derivatives:  Levlevofloxacin  is  a  quinolone/fluoroquinolone  antibiotic  related  to  ciprlevofloxacin,  enoxacin, 
fleroxacin,  gatifloxacin,  gemifloxacin,  grepafloxacin,  lomefloxacin,  moxifloxacin,  norfloxacin,  levofloxacin,  pefloxacin, 
prulifloxacin, rufloxacin, sparfloxacin, temafloxacin, trovafloxacin, sitafloxacin.
1.12 Specification::
Table 5 . Specification of Levofloxacin
Characteristics Light yellowish crystalline powder
Identification Positive
Solubility Positive
Loss on drying ≤4.0%
Heavy metals ≤20ppm
Residue on ignition ≤0.2%
Specific rotation -95° To -103°
Other impurities ≤0.32%
Assay 98.5%-99.5%
1.13 Overdose:  n the event of an acute overdosage, the stomach should be emptied. The patient should be observed and 
appropriate hydration maintained. Levlevofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.3
1.14 Pharmacology: Levlevofloxacin is the L-isomer of the racemate levofloxacin, a quinolone antimicrobial agent. In  
chemical terms, levlevofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug 
substance levofloxacin. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate. 
The empirical formula is C18H20FN3O4 • ½ H2O, and the molecular weight is 370.38. Levlevofloxacin is a light-yellowish-
white to yellow-white crystal or crystalline powder.3
Some of the endogenous compounds that are affected by the levlevofloxacin include GABA receptors (inhibitor), OCTN2 
(inhibitor),4 blood glucose (alteration) potassium channels (in myocardial cells - inhibitor),5 pancreatic β-cell potassium 
channels (inhibitor)115 and glutathione (depletor).
1.15 Pharmacokinetics: Levlevofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV 
dosing regimens. Levlevofloxacin is rapidly and, in essence, completely absorbed after oral administration. Peak plasma 
concentrations are usually attained one to two hours after oral dosing. The plasma concentration profile of levlevofloxacin 
after IV administration is similar and comparable in extent of exposure (AUC) to that observed for LEVAQUIN Tablets  
when equal doses (mg/mg) are administered. Levlevofloxacin is excreted largely as unchanged drug in the urine. The mean 
terminal plasma elimination half-life of levlevofloxacin ranges from approximately 6 to 8 hours following single or multiple 
doses of levlevofloxacin given orally or intravenously.3 Glucuronidation and hydroxylation have been cited as one of the 
major metabolic pathways for levlevofloxacin hydrochloride.6 However the drug card for levlevofloxacin states that the 
biotransformation information is not available.7 Specific information regarding biotransformation does not appear to be 
readily available within the package inserts. Half-life is 6–8 hours.7
1.16 Mechanism of action: Levlevofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and 
Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase iv,8 which is an 
enzyme necessary to separate replicated DNA, thereby inhibiting cell division.
The fluoroquinolones interfere with DNA replication by inhibiting an enzyme complex called DNA gyrase. This can also  
affect mammalian cell replication. In particular, some congeners of this drug family display high activity not only against  
bacterial topoisomerases but also against eukaryotic topoisomerases, and are toxic to cultured mammalian cells and in vivo  
tumor models. Although the quinolone is highly toxic to mammalian cells in culture, its mechanism of cytotoxic action is  
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not known. Quinolone-induced DNA damage was first reported in 1986.9 
Recent studies have demonstrated a correlation between mammalian cell cytotoxicity of the quinolones and the 
induction of micronuclei.10-13 As such some fluoroquinolones may cause injury to the chromosome of eukaryotic cells.14-19 
There continues to be debate as to whether or not this DNA damage is to be considered one of the mechanisms of 
action concerning the severe and non-abating adverse reactions experienced by some patients following fluoroquinolone 
therapy.20-22 
1.17 Interactions: The toxicity of drugs that are metabolised by the cytochrome P450 system is enhanced by concomitant  
use  of  some  quinolones.  Coadministration  may  dangerously  increase  warfarin  (Coumadin)  activity;  INR  should  be 
monitored closely.  They may also interact  with the GABA A receptor and cause neurological  symptoms; this effect  is  
augmented by certain non-steroidal anti-inflammatory drugs.23 Quercetin, a flavonol, a kind of flavonoid, occasionally used 
as a dietary supplement, may interact with fluoroquinolones, as quercetin competitively binds to bacterial DNA gyrase.  
Some foods such as garlic and apples contain high levels of quercetin;  whether this inhibits or enhances the effect  of  
fluoroquinolones is not entirely clear.24
Specific drug interaction studies have not been conducted with levlevofloxacin. However, the systemic administration of  
some  quinolones  has  been  shown  to  interfere  with  the  metabolism  of  caffeine,  elevate  plasma  concentrations  of 
theophylline,  and  enhance  the  effects  of  the  warfarin  and  its  derivatives.  In  patients  receiving  systemic  cyclosporine 
concomitantly, transient elevations in serum creatinine has been noted.25
1.18 Indications: apply to sensitive strains caused by : 
• Genitourinary  infections,  including  simple  and  complicated  urinary tract  infections,  bacterial  prostatitis,  urethritis  
Neisseria gonorrhoeae or cervicitis (including producing strains caused).
• Respiratory infections, including sensitive Gram-negative bacilli induced bronchial infection and acute lung infection. 
• Gastrointestinal tract infections, Shigella, Salmonella spp, Enterotoxigenic E. coli endotoxin, hydrophilic Aeromonas, 
such as Vibrio parahaemolyticus caused.
• Typhoid. Donor. Bone and joint infections. 
• Skin and soft tissue infections. 
• Septicemia systemic infection.
1.19 Significant drug interactions: Levlevofloxacin has been reported to interact with a significant number of other drugs, 
as  well  as  a  number  of  herbal  and  natural  supplements.  Such  interactions  increased  the  risk  of  cardiotoxicity  and 
arrhythmias, anticoagulant effects, the formation of non-absorbable complexes, as well as increasing the risk of toxicity.
Some drug interactions are associated with molecular structural modifications of the quinolone ring, specifically interactions 
involving NSAIDS and theophylline.  The fluoroquinolones have also been shown to interfere with the metabolism of 
caffeine 172 and the absorption of levothyroxine. The interference with the metabolism of caffeine may lead to the reduced  
clearance of caffeine and a prolongation of its serum half-life, resulting in a caffeine overdose. Ciprlevofloxacin has been  
shown to interact with thyroid medications (levothyroxine) resulting in unexplained hypothyroidism.26 As such it is possible 
that levlevofloxacin may interact with thyroid medications as well.
1.20 Adverse effects: The serious adverse effects that may occur as a result of levlevofloxacin therapy include irreversible 
peripheral neuropathy,27 spontaneous tendon rupture and tendonitis, QTc prolongation/torsades de pointes, toxic epidermal 
necrolysis (TEN) and Stevens-Johnson syndrome,  erythema multiforme, severe central nervous system disorders (CNS), 
including  seizures28 and  clostridium  difficile  associated  disease  (CDAD:  Pseudomembranous  colitis)29-32 
photosensitivity/phototoxicity reactions,33 fatal hypoglycemia, kidney damage, rhabdomyolysis (muscle wasting),34,35 as 
well as anaphylactoid reactions36 and myasthenia crisis.37
1.20.1 Paediatrics: Safety not established.
1.20.2 Pregnancy & Lactation: Safety not established.
1.20.3 Elderly: Safe.
2.21  Side-Effects:  Mild  transient  smarting  sensation  and  itching.  Temporary  blurred  vision,  eye  discomfort,  itching, 
redness, dryness, tearing, feeling as if something is in your eye, or sensitivity to light may occur.
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1.22  Purity : Not less than 99%.
1.23  Contraindication: The  use  of  eye  drop  Levofloxacin  is  contraindicated  in  patients  with  hypersensitivity  to  
Levofloxacin or to other quinolones or to any of the components of the medication. 
1.24  Uses:This  medication  is  used  to  treat  eye  infections.  Levofloxacin  belongs  to  a  class  of  drugs  called  quinolone 
antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work 
for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.
1.25 Storage: Preserve in well-closed containers, protected from light. Store at 25 excursions permitted between 15 and 30 .
2. Preformulation Study
2.1 Method: Identification of Drug: 38  
2.1.1 UV Spectrophotometric analysis of drug: Ultraviolet absorption in the range 200 to 400 nm of a 25 mg/ml solution in 
methanol was determined.
2.1.2 Fourier Transform Infra Red analysis of drugs:  The FTIR analysis of the sample was carried out for qualitative 
compound identification. The KBr pellet of approximately 1 mm diameter of the drug was prepared grinding 3-5 mg of  
sample with 100-150 mg of KBr in pressure compression machine. The infrared spectrum of levofloxacin in a KBr pellet  
for wave number range of 4000– 500 cm-1 
Preparation Of Buffers And Reagents: 39
• Sodium hydroxide solution 0.2 M – 8.0 gm of sodium hydroxide was dissolved in distilled water and diluted to 1000  
ml with distilled water.
• Potassium dihydrogen phosphate solution 0.2 M – 27.218 gm of potassium dihydrogen phosphate was dissolved in  
distilled water and diluted to 1000 ml..
• Phosphate  buffer  solution  PH  7.4  –  250  ml  of  0.2  M  potassium dihydrogen  phosphate  was  placed  in  1000  ml 
volumetric flask. 112 ml of 0.2 M sodium hydroxide was added and then volume was adjusted with distilled water up  
to 1000 ml. PH was adjusted to 7.4 with dilute sodium hydroxide.
Quantitative Estimation Of Drug:
• Determination of absorption maxima (λmax)/wavelength maxima – The standard sock solution of levofloxacin was 
prepared by dissolving 50 mg of drug in methanol in 100 ml volumetric flask. Stock solution of Levofloxacin was  
further  diluted in methanol to get  standard solution concentration of 100 mcg/ml.  The resulting solution was then  
scanned between 200 -400 nm. UV visible spectrophotometer (shimadzu 1601 UV Japan). 38
• Standard curve of levofloxacin in phosphate buffer solution (PH 7.4) Accurately weighed 100 mg of levofloxacin 
was dissolved in 100 ml of pH 7.4 phosphate buffer to give a solution of 1 mg/ml (1000 µg/ml) concentration and thi  
served as the first standard stock solution. From this stock solution 1 ml was taken and diluted to 100 ml using pH 7.4  
phosphate buffers to get a solution of 10 µg/m concentration and this solution served as the second standard solution. 
Into a series of 10 ml volumetric flasks, aliquots of second standard solution (i.e.) 2 ml, 4 ml, 6 ml, 8ml, 10ml and 12  
ml was added and the volume made up to 10 ml using pH 7.4 phosphate buffer. The absorbance of these solutions was  
measured against  reagent blank at 292 nm using Shimadzu (UV-1601) UV spectrophotometer.  Standard curve was 
plotted with concentration on x-axis and absorbance on y-axis
2.2 Preformulation Study Of Drug: Preformulation studies are needed to ensure the development of a stable as well as 
therapeutically  effective  and  safe  dosage  form.40,41 The  Preformulation  studies,  performed  in  this  research  include 
identification of drug, solubility analysis, partition coefficient and drug compatibility. 42,43
• Solubility determination:-  For quantitative solubility studies,  known amount of drug (10mg) was suspended in a 
series of different solvents and shaken for 24 hrs. Using wrist action shaker (York India). Solubility of levofloxacin in  
different solvents is recorded.44-47
• Melting point determination:- Melting point determination of levofloxacin is done by using Melting Point Apparatus. 
In that method the presealed capillary is filled by the small amount of drug. Then capillary and thermometer were 
placed in Melting Point Apparatus. Then see capillary for melting the drug. The temperature were noted when the drug 
start to melt and the drug till complete melt.
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• Partition  coefficient  determination:-  The partition  coefficient  of  Levofloxacin  was  determined  by shaking  flask 
method in n-octanol: water system. 10 mg of drug Levofloxacin was added into 50 ml each of n-octanol and water. The 
mixture was shaken for 24 hours until equilibrium was reached. Phases were separated in a separating funnel and the  
aqueous phase was filtered through 0.2µ filter, suitably diluted and amount of Levofloxacin in aqueous phase was  
determined by measuring the absorbance at 258nm using UV spectrophotometer. The partition coefficient (Po/w) of 
Levofloxacin was calculated from the ratio between the concentration of Levofloxacin in organic (Coil) and aqueous 
phase (Caq.) using following equation.
 Po/w = (Coil/Caq.) equilibrium
3. Results And Discussion
3.1 Organoleptic Properties
3.1.1 Colour: Yellowish white.
3.1.2 Crystalinity: crystalline powder. 
3.1.3 Hygroscopicity: No Hygroscopicity
3.1.4 Taste: Bitter
3.1.5 Odour: odorless
3.2 Identification of Drug 
3.2.1 Determination of λmax: The λmax was found to be at 293 nm . 
4. Discussion: 
λmax is 293. The obtained peak was found to be identical  to the reported absorbance maxima. This λmax is 
matches with the λmax given in I.P.
4.1  FT-IR Study for identification of drug:  An FT infrared (FT-IR) spectroscopy study was carried out to check the 
compatibility between the drug levofloxacin. The spectra obtained from FT infrared spectroscopy studies at wavelength 
from 4000 cm to 400-1 cm are shown Figures characteristic peaks obtained.
This study was carried out to find out the possible drug levofloxacin . FT-IR of levofloxacin showed the following 
characteristic peaks peak at 3265-1 cm due to carboxylic group 2931-1 cm due to alkanes group stretching 1724-1 cm due to 
stretching of carbonyl group, 1294-1 cm due to stretching of amines, in between 1100 to 1400-1 cm due to the presence of 
halogen group. thus revealing compatibility of the selected drug
Fig no 1. FTIR interpretation of levofloxacin
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-COOH -CH3 C=O C-N F (halogen group
Levofloxacin (standard) 3265 2931 1724 1294 1085
Levofloxacin drug 3265.59 2931.90 1724.42 1294.26 1085.96
4.2 Calibration Curve: Standard curve of levofloxacin in phosphate buffer solution (PH 7.4)
Table 2: Absorbance value of levofloxacin in PBS pH 7.4 (λmax 292 nm).






Fig 2: Standard curve of levofloxacin in PBS pH 7.4 (λmax 292 nm).
4.3 Solubility properties: Solubility of levofloxacin in different solvents is recorded.
Table 3 : Solubility of levofloxacin in different solvent.
Solvent Solubility
Water Slightly soluble
Glacial acetic acid Freely soluble
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4.4 Partition Coefficient: The partition coefficient of Levofloxacin was determined in n-octanol: water system at pH 7.4  
buffers.
Test Specification Observation
Partition coeff. n-octanol:pbs (7.4) 4.3
.4.5 Melting Point: Melting Point of Levofloxacin is 224oC
5. Discussion: 
Melting point of the drug Levofloxacin is found 224 oC, which is approx. same as reported in I.P 2007 so it shows 
the purity of the drug. The melting point of the drug is found in 225-227°C range this shows that, the drug is amorphous in  
nature.
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